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A B S T R A C T
The aim of the study was to determine cardiovascular drugs utilization and quality of prescribing in Croatia from
2003 to 2008. Data on the outpatient utilization of cardiovascular drugs in Croatia were collected during 2003–2008.
Data on the size and number of packages, were obtained from Croatian institute for Health Insurance (CIHI). Based on
the data obtained, the numbers of DDD and DDD per 1000 inhabitants per day (DDD/1000/day) were calculated for all
cardiovascular drugs. Quality of drugs prescribing was assessing using Drug Utilization 90% (DU90%) method. Re-
nin-angiotensin system agents showed highest share in the utilization of group C drugs, followed by calcium channel
blockers. These two groups of drugs accounted for half of the overall cardiovascular drug utilization. Greatest changes
were observed in the groups of renin-angiotensin system agents and hypolipemics. The number of drugs within DU90%
segment increased between 2003 and 2008. In the same period Cost/DDD decreased.
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Introduction
There is a constant rise in drug sales at the world
market. In the past 12 months, a 6% rise in drug utiliza-
tion was recorded at 13 leading world markets1. In
Croatia, the group of cardiovascular drugs, i.e. group C in
the Anatomical-Therapeutic-Chemical (ATC) classifica-
tion of drugs, has for years been the leading group of
drugs according to utilization2,3. At the same time, car-
diovascular diseases are the leading cause of morbidity
and mortality, and the leading cause of hospitalization in
Croatia4. All these indicators pointed to the need to as-
sess the use of cardiovascular agents and their prescrib-
ing quality by use of the WHO Anatomical Therapeutic
Chemical/Defined Daily Dose (ATC/DDD) methodology
as a standard method of drug utilization monitoring at
the population level, providing an insight into the real
drug utilization irrespective of price, and allowing for
comparison with other settings5–8. For these reasons, we
embarked upon the present study to estimate the distri-
bution of cardiovascular drug utilization in Croatia, and
to assess the quality of cardiovascular drug prescribing
at primary health care (PHC) level in Croatia. The re-
sults thus obtained were used to propose a set of most ef-
ficient measures for rationalization of cardiovascular
drug utilization.
Material and Methods
Data on the outpatient utilization of cardiovascular
drugs (ATC group C) in Croata were collected during,
2003, 2004, 2005, 2006, 2007 and 2008. Data on the size
and number of packages, and financial data based on
wholesale price were obtained from Croatian institute
for Health Insurance (CIHI). All drugs were classified ac-
cording to ATC system. Based on the data obtained, the
numbers of DDD and DDD per 1000 inhabitants per day
(DDD/1000/day) were calculated for all cardiovascular
drugs using ATC indexes with DDD for 2003, 2004, 2005,
2006, 2007 and 20089–14.
Operational definitions:
Number of DDDs = Number of packages sold ´ DDD
of the package
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DDD per 1000 inhabitants per day = Total consump-
tion in DDDs ´ 1000
Covered inhabitants ´ Days in the period of data collec-
tion (365 days – one year)
On DDD/1000/day calculation, data from the latest
2001 census were used, according to which the popula-
tion of the Croatia was 4.437.460. Total outpatient utili-
zation of ATC group C prescription drugs, utilization dis-
tribution of this drug group at secondary, tertiary and
quaternary level, and consumption of individual drugs
were analyzed. Utilization of drugs included in the List
of Drugs of the Croatian Institute of Health Insurance
(CIHI), i.e. prescription drugs, was investigated. Rela-
tions of all modifications made in drug legislation during
the 2003–2008 period in Croatia, which may have influ-
enced the quality of drug prescribing, were analyzed. The
Drug Utilization 90% (DU90%) method was used as a cri-
terion of prescribing quality15,16. Additional indicators of
rational drug utilization were also determined, e.g., cost
per DDD within DU90% segment (cost/DDD); cost/DDD
for drugs beyond DU90% segment; and cost/DDD for all
cardiovascular drugs.
Results
Renin-angiotensin system agents showed highest sha-
re in the utilization of group C drugs, followed by calcium
channel blockers. These two groups of drugs accounted
for half of the overall cardiovascular drug utilization.
Greatest changes were observed in the groups of renin-
-angiotensin system agents and hypolipemics; their utili-
zation increased from 2003 to 2008 by 150%. The greatest
utilization decline was recorded in the group of cardiac
agents (C01), whereas C02 group showed lowest utiliza-
tion modification during the study period (Table 1).
The number of drugs within DU90% segment in-
creased between 2003 and 2008 (Table 2 and Table 3).
The number of C09 group drugs showed a rise (from 7 in
2003 to 9 in 2008). In this group, the use of lisinopril that
predominated in 2003 was reduced by half, while the use
of angiotensin II antagonists (II-C09C; losartan, val-
sartan) increased until 2008. The use of hypolipemics
also showed a significant increase; in 2008, atorvastatin
and simvastatin ranked second and third according to
group C drug utilization.
In the same period Cost/DDD decreased.
Discussion
From 2003 to 2008, the number of drugs within
DU90% segment increased by one agent. The number of
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TABLE 1
OUTPATIENT UTILIZATION OF ATC GROUP C DRUG GROUPS
AT SECONDARY ATC SYSTEM LEVEL EXPRESSED AS
DDD/1000/DAY IN CROATIA 2003–2008
ATC code 2003 2004 2005 2006 2007 2008
C01 31.86 30.11 29.54 32.63 26.66 26.59
C02 7.00 6.66 6.60 7.50 6.57 6.56
C03 40.40 41.11 35.85 39.86 38.78 40.81
C07 22.70 22.53 22.70 25.36 25.32 27.88
C08 55.73 56.19 59.55 64.22 69.56 76.77
C09 53.69 58.97 59.85 70.16 125.36 142.40
C10 29.99 36.09 36.03 46.21 59.41 74.62
Total 241.37 250.44 250.28 286.43 351.69 396.27
Legend: C01 – cardiac agents; C02 – antihypertensive agents;
C03 – diuretics; C07 – b-blockers; C08 – calcium channel blockers;
C09 – renin-angiotensin system agents; C10 – hypolipemics
TABLE 2
DRUGS WITHIN DU90% SEGMENT, THEIR SHARE IN GROUP C
UTILIZATION, COST per DEFINED DAILY DOSE (COST/DDD)
EXPRESSED IN HRK WITHIN DU90% SEGMENT AND TOTAL
COST/DDD IN 2003
No
2003
INN-generic name of drug %
1 amlodipine 12.07
2 lisinopril 10.30
3 simvastatin 8.18
4 furosemide 7.25
5 atenolol 6.64
6 lisinopril + hydrochlorothiazide 5.90
7 isosorbide mononitrate 4.87
8 atorvastatin 3.85
9 verapamil 3.79
10 lacidipin 3.41
11 cilazapril 3.03
12 ramipril 2.98
13 doxazosin 2.74
14 propafenone 2.30
15 nifedipine 2.09
16 chlorthalidone 1.99
17 methyl digoxin 1.82
18 cilazapril + hydrochlorothiazide 1.27
19 bisoprolol 1.26
20 indapamide 1.24
21 amiodarone 1.21
22 losartan 0.92
23 losartan + hydrochlorothiazide 0.82
Total (%) 89.93
Number of drugs within DU90% segment 23
Total number of drugs** 67
Total cost/DDD 2.40
Cost/DDD within DU90% segment 2.38
Cost/DDD beyond DU90% segment 2.58
*share in total group C prescription drug utilization expressed
as number of DDD/1000/day according to generic names of drugs
included in the CIHI List of Drugs in particular year; **total
number of group C drugs included in the CIHI List of Drugs in
particular year
C01 drugs within DU90% segment was four in 2003 and
three in2008, including the same agents, i.e. isosorbide
mononitrate, propafenone and methyl digoxin; however,
the utilization of these agents decreased significantly
during the study period. The utilization of methyl di-
goxin was 7,05DDD/1000/day and 4,96 DDD/1000/day in
2003 and 2008, respectively. The indications for the use
of this drug include acute and chronic cardiac decom-
pensation and some supraventricular arrhythmias17,18.
However, due to the potential side effects, primarily car-
diac rhythm disturbance, digitalis glycosides are cur-
rently administered only as the fourth-choice therapy for
chronic cardiac decompensation, after ACE inhibitors,
b-blockers and diuretics; and for acute cardiac decom-
pensation in the presence of peripheral hypoperfusion
with congestion or pulmonary edema refractory to di-
uretics and vasodilators in optimal dosage18. Therefore,
the reduced utilization of this agent is justifiable, and it
is anticipated to disappear from DU90% segment in the
future. Propafenone belongs to the group of antiarrhy-
thmics, indicated for the treatment of supraventricular
cardiac rhythm disturbances19. The use of propafenone
also decreased from 8,87 DDD/1000/day in 2003 to 5,06
DDD/1000/day in 2008. Amiodarone, another antiarrhy-
thmic, was present within DU90% segment in 2003. In
addition to its potent antiarrhythmic action, thus now
widely used instead of lidocaine on resuscitation, long-
-term use of amiodarone is associated with a number of
side effects19. Propafenone also leads to various side ef-
fects, including exacerbation of heart failure and pro-
arrhythmic effect as the most severe ones19. Although
antiarrhythmic agents have their place in therapy, they
should always be administered with caution. It should be
noted that not all arrhythmias require treatment. Group
I agents including propafenone are not recommended for
use at long-term, especially in patients with coronary dis-
ease. Group III agents are considered as being safe for
cardiac patients19–24. According to CIHI provisions, these
drugs can be restrictively prescribed exclusively on the
internist’s recommendation25,26. Yet, given the high utili-
zation of these agents, it is questionable to what extent
the Croatia PHC practitioners do comply with this regu-
lation. Comparison of our indicators with those on Scan-
dinavian countries revealed the utilization of antiar-
rhythmics to be ten times lower in the latter27,28. Based
on these scientific data, it is obvious that these agents,
propafenone in particular, should not be found within
DU90% segment, as they actually are in Croatia, with
quite a high rate of utilization.
Isosorbide mononitrate is the third group C01 agent
recorded within DU90% segment throughout the 6-year
study period. During this period, the utilization of iso-
sorbide mononitrate showed an almost twofold decline,
from 18,83 DDD/1000/day in 2003 to 11,47 DDD/1000/
day in 2008, still reflecting quite a high rate of utiliza-
tion, yet at the level recorded in Scandinavian coun-
tries27,28. The indications for prescribing nitrates include
prophylaxis of angina pectoris and treatment of heart
failure18. In case of stable angina pectoris, b-adrenergic
receptor blockers are therapy of choice, whereas nitrates
are only used as the second- or third-choice agents18. Ni-
trates have their place in the management of acute heart
failure and pulmonary edema29–31. However, all nitrates
lead to tolerance and their long-term and frequent use is
wrong32,33. In this context, the high utilization of iso-
sorbide mononitrate in Croatia is a highly questionable
issue. The significant reduction in the utilization of car-
diac agents is in line with the respective guidelines and
scientific concepts, and it is expected to continue in the
future, of cardiac glycosides in particular.
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TABLE 3
DRUGS WITHIN DU90% SEGMENT, THEIR SHARE IN GROUP C
UTILIZATION, COST per DEFINED DAILY DOSE (COST/DDD)
EXPRESSED IN HRK WITHIN DU90% SEGMENT AND TOTAL
COST/DDD IN 2008
No
2008
INN-generic name of drug %
1 amlodipine 12.63
2 atorvastatin 9.14
3 simvastatin 7.80
4 lisinopril + hydrochlorothiazide 7.56
5 ramipril 7.41
6 lisinopril 7.06
7 furosemide 6.85
8 lacidipin 4.49
9 atenolol 3.17
10 isosorbide mononitrate 2.90
11 bisoprolol 2.27
12 ramipril+ hydrochlorothiazide 2.10
13 losartan + hydrochlorothiazide 1.79
14 fluvastatin 1.61
15 losartan 1.55
16 trandolapril 1.39
17 indapamide 1.32
18 doxazosin 1.31
19 cilazapril 1.30
20 propafenone 1.28
21 cilazapril + hydrochlorothiazide 1.27
22 chlorthalidone 1.27
23 methyl digoxin 1.26
24 verapamil 1.12
Total (%) 89.88
Number of drugs within DU90% segment 24
Total number of drugs** 72
Total cost/ddd 1.58
Cost/DDD within DU90% segment 1.50
Cost/DDD beyond DU90% segment 2.27
*share in total group C prescription drug utilization expressed
as number of DDD/1000/day according to generic names of drugs
included in the CIHI List of Drugs in particular year; **total
number of group C drugs included in the CIHI List of Drugs in
particular year
The utilization of C02 group, almost exclusively refer-
ring to doxazosin, also showed a declining tendency dur-
ing the study period (Table 1). Doxazosin was the only
C02 group agent within DU90% segment, where it ran-
ked high (Table 2) throughout the 6-year period, al-
though its utilization decreased during the study period,
i.e. from 6,59 DDD/1000/day in 2003 to 5,19 DDD/1000/
day in 2008. Doxazosin is an  -adrenergic receptor blo-
cker (C02CA), thus belonging to the group of antihy-
pertensive agents. However, the role of doxazosin in the
management of hypertension has now been considerably
reduced based on the studies demonstrating its use to be
associated with a higher mortality rate in patients with
heart failure. Therefore, this agent is currently used only
in patients with benign prostate hyperplasia, for its re-
laxing effect on the prostate smooth muscle and urinary
flow improvement34–36. Thus, this agent appears to re-
quire reclassification in the ATC system. Benign prostate
hyperplasia is a common problem in elderly men; how-
ever, the utilization of doxazosin in Croatia greatly ex-
ceeds its utilization in other settings27,28, and it can be
considered neither justifiable nor appropriate.
In spite of an increase in 2004 relative to the previous
year, in 2005 the utilization of diuretics decreased by
22.03% in comparison with 2003. From 2005 diuretics
showed increasing trend, so utilization of C03 group in
2008 is almost the same as in 2003. During the study pe-
riod, the utilization of furosemide, a potent diuretic pri-
marily used in the management of all types of edema37,
decreased in 2005, but increased again in 2008. The utili-
zation of chlorthalidone, primarily used as an antihyper-
tensive agent37, declined in study period, whereas the
utilization of indapamide, firstly used in mild to moder-
ate hypertension17, increased. Indapamide has some ad-
vantages over chlorthalidone; however, it is more expen-
sive, thus raising the question of rational drug pre-
scribing37,38. Although diuretics yield only symptomatic
effects and cannot reduce mortality when administered
for the management of hypertension, they are still used
as first-choice agents because of their low price, in el-
derly patients and for moderate, uncomplicated hyper-
tension in particular39,40.
Comparing the utilization of diuretics in Croatia and
other settings showed it to be lower in Croatia and, al-
though many cost-effectiveness studies prefer this group
of agents for the management of hypertension39,40.
The group of b-blockers showed an increasing utiliza-
tion pattern since 2004. b-blockers play an important
therapeutic role because of their efficacy in the manage-
ment of arterial hypertension, coronary disease and cer-
tain arrhythmias, in secondary prevention of myocardial
infarction, and for their favorable effects in cardiac fai-
lure41,42. Along with atenolol, bisoprolol also was present
in DU90% segment throughout the 6-year study period.
These two agents are selective blockers of b1-adrenergic
receptors which, while showing some pharmacokinetic
variability, have very similar effects42. Although biso-
prolol as a considerably more expensive drug can only be
prescribed upon specialist’s recommendation according
to CIHI List of Drugs provisions, its utilization increased
from 2003–2008. At the same time, the utilization of
atenolol, although still exceeding the utilization of other
b-blockers, declined. In the therapeutic subgroup of se-
lective b-blockers, prescribing a more expensive drug is
not justifiable because it has not yet been substantiated
by professional and scientific evidence41,42.
Utilization of calcium channel blockers as the second
subgroup according to utilization in the group of cardio-
vascular agents showed a rising pattern until 2008. Ac-
cording to European guidelines43, these agents are con-
sidered more efficient than diuretics and a-blockers in
preventing the development of atherosclerosis and are
therefore recommended for the treatment of angina pec-
toris and carotid atherosclerosis. Their greater use at the
PHC level could be related to the significant reduction in
the rate of hospitalization for ischemic heart disease and
cerebrovascular disease. Four drugs from this group we-
re present in DU90% segment in 2003 and three drugs in
2008. From 2003, amlodipine was the leading agent ac-
cording to utilization both in the group of cardiovascular
drugs and in the overall outpatient drug utilization in
the Croatia. Its utilization increased from 32.26 DDD/
1000/day in 2003 to 49,95 DDD/1000/day in 2008 (36%
increase). The utilization of lacidipin,, increased twice
during the study period (from 8.40 DDD/1000/day in
2003 to 17.77 DDD/1000/day in 2008). At the same time,
the utilization of nifedipine decreased twice (from 6.31
DDD/1000/day in 2003 to 3.36 DDD/1000/day in 2008), so
it was not in DU90% segment in 2008. The use of vera-
pamil, the only selective calcium channel blocker with di-
rect cardiac effects within DU90% segment, declined also
twice (from 8.93 DDD/1000/day in 2003 to 4.43 DDD/1000/
day in 2008). Because of their prolonged action and abil-
ity of baroreceptor adaptation, amlodipine and lacidipin
have considerable advantages over short-acting nifedipi-
ne, which is not recommended even in hypertensive crisis
anymore due to the induction of reflex tachycardia43–45.
However, lacidipin is much more expensive than amlo-
dipine and even more so than nifedipine. The utilization
of lacidipin increased at a higher rate than that of amlo-
dipine, while the utilization of nifedipine declined. As the-
se three agents belong to the same therapeutic group and
exert very similar or identical effects, the considerably
higher rate of prescribing the most expensive drug has
no grounds in professional and scientific evidence43–45.
The subgroup of renin-angiotensin system agents
(C09) showed highest utilization in the group of cardio-
vascular drugs. The overall utilization of C09 group
showed no major modifications during the study period,
however, the distribution of particular agents within this
subgroup underwent significant changes, as evidenced
by the number of these drugs present in DU90% seg-
ment. In 2003, seven agents were present in DU90% seg-
ment, three of them pure ACE inhibitors (C09A): li-
sinopril, cilazapril and ramipril; and a combinations with
diuretic (C09B): (lisinopril + hydrochlorothiazide, cila-
zapril + hydrochlorothiazide); losartan, a pure angioten-
sin II antagonist (C09C); and losartan + hydrochlorothi-
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azide, a combination of an angiotensin II antagonist with
a diuretic (C09D). In 2008, trandolapril, and ramopril +
hydrochlorothiazide joined the drugs already present in
DU90% segment. During the study period, the utiliza-
tion of pure ACE inhibitors increased by 27% (from 53.95
DDD/1000/day in 2003 to 74.42 DDD/1000/day in 2008).
The utilization of combinations of ACE inhibitors with
diuretics increased more than twice (from 21.63 DDD/
1000/day in 2003 to 50.50 DDD/1000/day in 2008). The
utilization of pure angiotensin II antagonists increased
from 5.02 DDD/1000/day in 2003 to 9.07 DDD/1000/day
in 2008. Combinations of angiotensin II antagonists with
diuretics showed constant increase in utilization (3.16
DDD/1000/day in 2003, and 8.42 DDD/1000/day in 2008).
ACE inhibitors currently are first-choice therapy in the
management of chronic cardiac decompensation and hy-
pertension, in diabetic patients in particular46–48. Mem-
bers of the subgroup of pure ACE inhibitors have very
similar or identical clinical effects. Consequently, WHO
included enalapril in the List of Essential Medicines be-
cause of its lowest price46. In Croatia, however, enalapril
was not present among 90% of most frequently prescribed
drugs, while more expensive drugs from the same group
were included. The use of angiotensin II antagonists in-
creased. These agents are associated with less side effects
and are more efficacious than ACE inhibitors only in dia-
betic nephropathy47–51. Their price is high; therefore,
CIHI restricted their use only to patients that cannot tol-
erate ACE inhibitors, and can only be prescribed on in-
ternist’s recommendation25,26. It remains to estimate the
extent to which the increasing prescribing expensive
drugs in spite of CIHI guidelines, in cases when there are
as efficacious but less expensive drugs, is based on the
real patient needs or on the influence of pharmaceutical
industry marketing on PHC physicians or specialists.
Outpatient utilization of expensive hypolipemics rose
more than twofold from 2003 to 2008. In 2003, only
simvastatin was ranked third, and atorvastatin eight in
DU90% segment. In 2008 these two agents ranked sec-
ond and third according to utilization in the group of car-
diovascular drugs. During the study period, the utiliza-
tion of atorvastatin increased forefold (8.99 DDD/1000/
day in 2003, and 36.17 DDD/1000/day in 2008). There are
no substantial differences between these drugs, and sim-
vastatin has a lower price per DDD than atorvastatin.
Statins have been demonstrated to be efficient in lower-
ing elevated serum lipid levels, cholesterol in particular,
and to have a beneficial effect on decreasing morbidity
and mortality from cardiovascular complications52–54. Be-
cause of their efficacy these drugs have been included in
the List of Essential Medicines46, however, with the same
prescribing restrictions found in the CIHI List of
Drugs25,26. Namely, due to their very high price, prescrib-
ing these drugs is indicated for secondary prevention in
patients with myocardial infarction, stroke, or ultra-
sonography demonstrated carotid plaque, or coronary
disease demonstrated by coronarography, and in diabetic
patients with total cholesterol exceeding 5 mmol/L. In
primary prevention, prescribing these agents is restricted
to patients with total cholesterol exceeding 7 mmol/L on
two laboratory tests performed three months apart, after
3-month dietary regimen25,26. As 25% to 75% prescription
charge is paid for these drugs25,26, the significant increase
in their utilization recorded from 2003 could be related
to the introduction of supplementary health insurance. A
growing tendency of hypolipemic utilization is recorded all
over the world54–57; however, it should be borne in mind
that diet is the basic preventive and therapeutic measure
in the management of most common hyperlipidemias56.
Analysis of the cardiovascular drug prescribing qual-
ity and adherence to professional guidelines indicated
the prescribing quality to have definitely improved. The
number of drugs within DU90% segment increased, indi-
cating a diversified, more individualized and patient ad-
justed therapeutic approach. Apart from doxazosin, the
presence of which within 90% of most widely prescribed
drugs had no professional grounds, and antiarrhythmics,
propafenone in particular, other drugs were generally
consistent with professional guidelines. CIHI indications
were justified in case of prescribing statins and angioten-
sin II antagonists, considering the high price and very
high utilization of these agents. The price/DDD ratio in
total drug utilization and within DU90% segment was
highest in 2003, which was additionally favored by the
introduction of supplementary health insurance, thus ex-
empting a great proportion of patients from paying pre-
scription charge. This entailed considerable increase in
the utilization of expensive hypolipemics. The price/ DDD
ratio within DU90% segment was lower in 2008; how-
ever, the Regulations on calculating wholesale drug prices,
adopted in 200457, reduced the prices of most very expen-
sive drugs found within DU90% segment from 2005–2008.
Conclusion
Although showing some quality improvement, the
utilization of cardiovascular agents resulting from avail-
ability of newer drugs and their introduction in the List
of Drugs is not rational, suggesting that physicians in
Croatia fail to comply with CIHI guidelines and mostly
prescribe drugs irrespective of their price, even when
there is a less expensive and as efficient agent from the
same therapeutic group (e.g., lisinopril, ramipril or cila-
zapril instead of enalapril; lacidipin or amlodipine in-
stead of intermediary-acting nifedipine). Introduction
the Regulations on calculating wholesale drug prices,
was the measure that improve farmacoeconomics indica-
tors in Croatia.
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KVALITETA PROPISIVANJA KARDIOVASKULARNIH LIJEKOVA U REPUBLICI HRVATSKOJ OD
2003–2008
S A @ E T A K
Cilj ovoga rada je utvrditi izvanbolni~ku potro{nju i kvalitetu propisivanja kardiovaskularnih lijekova na razini
primarne zdravstvene za{tite od 2003–2008. godine u Republici hrvatskoj. Podaci o veli~ini i broju pakovanja za sve
propisane kardiovaskolurane lijekove u razdoblju od 2003–2008. godine dobiveni su od Hrvatskog zavoda za zdrav-
stveno osiguranje (HZZO). Na temelju podataka o broju pakovanja izra~unat broj utro{enih definiranih dnevnih doza
(DDD) i broj definiranih dnevnih doza na 1000/stanovnika/dan (DDD/1000/dan) za sve kardiovaskularne lijekove. Kva-
liteta propisivanja ocjenjena je DU90% metodom. Najve}eg udjela u potro{nji kardiovaskularnih lijekova imaju pro-
pravci s u~inkom na renin-angiotenzinski sustav te zatim, blokatori kalcijevih kanala. Ove dvije skupine ~ine vi{e od
polovice ukupne potro{nje kardiovaskularnih lijekova. Najve}e promjene u potro{nji u promatranom razdoblju bilje`e
skupine hipolipemika i lijekova s u~inkom na rennin-angiotenzinski sustav. U promatranom rarazdoblju broj lijekova
unutar DU90% segmenta je porastao, kao i kvaliteta propisivanja, dok se tro{ak/DDD smanjio.
D. [timac: Cardiovascular Drugs Prescribing, Coll. Antropol. 36 (2012) Suppl. 1: 189–194
194
